Literature DB >> 17905466

Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival.

Birgit Guldhammer Skov1, Barbara M Fischer, Helle Pappot.   

Abstract

BACKGROUND: Adenocarcinoma of the lung is more frequent in females than in males and the association with smoking is less pronounced than for the other histological subtypes of lung cancer. Oestrogen induction of cell proliferation has been found in breast adenocarcinomas, and since oestrogen receptors (ER) have been demonstrated in lung tumours, a similar role of oestrogens in the development of lung cancer has been suggested. We examined the expression of ERalpha, ERbeta and progesterone in a well defined cohort of patients with NSCLC with more than 15 years of follow up, and related the results to gender and survival.
METHODS: Paraffin embedded, histological material was collected from 104 patients (71 men and 33 women), operated in the period 1989-1992 for NSCLC (56 squamous cell carcinomas, 40 adenocarcinomas and 8 large cell carcinomas). ERalpha, ERbeta and progesterone were immunohistochemically analysed. Staining frequency and intensity was scored semi-quantitatively. A tumour was defined as positive when more than 10% of the tumour cells were positive with at least a weak nuclear staining. Kaplan-Meier survival curves were generated to evaluate the significance of ERalpha, ERbeta and progesterone expression for the prognosis.
RESULTS: ERbeta positivity was demonstrated in 69% (72 of 104) of the tumours. There was no statistically significant correlation between ERbeta positivity and age, gender, stage, or histology. After adjusting for gender, age, stage at diagnosis and histology there was no difference in survival between subjects with ERbeta positive and ERbeta negative tumours. When stratifying by gender women with ERbeta-negative tumours had a non-significant (P=0.26) decrease in mortality compared with women with ERbeta positive tumours. In contrast, men with ERbeta positive tumours had a significantly reduced mortality (P=0.035) compared to men with ERbeta negative tumours. Using multivariate regression analysis the interaction between gender and positive ERbeta staining was the only significant prognostic factor. There was no correlation between the ERalpha immunohistochemical staining and any of the clinical variables, including survival. None of the 104 patients had tumours positive for progesterone.
CONCLUSION: The presence of ERbeta in a tumour seems to be a positive prognostic factor for men with non-small cell lung cancer. The finding confirms another recent study and suggests that the relation between oestrogens and lung cancer be investigated further.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17905466     DOI: 10.1016/j.lungcan.2007.07.025

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  56 in total

1.  Targeting the estrogen pathway for the treatment and prevention of lung cancer.

Authors:  Timothy F Burns; Laura P Stabile
Journal:  Lung Cancer Manag       Date:  2014-02-01

2.  Expression levels of estrogen receptor beta in conjunction with aromatase predict survival in non-small cell lung cancer.

Authors:  Vei Mah; Diana Marquez; Mohammad Alavi; Erin L Maresh; Li Zhang; Nam Yoon; Steve Horvath; Lora Bagryanova; Michael C Fishbein; David Chia; Richard Pietras; Lee Goodglick
Journal:  Lung Cancer       Date:  2011-04-20       Impact factor: 5.705

3.  Differential role of estrogen receptor beta in early versus metastatic non-small cell lung cancer.

Authors:  Sri Navaratnam; Georgios Skliris; Gefei Qing; Shantanu Banerji; Ketan Badiani; Dongsheng Tu; Penelope A Bradbury; Natasha B Leighl; Frances A Shepherd; Janet Nowatzki; Alain Demers; Leigh Murphy
Journal:  Horm Cancer       Date:  2012-06       Impact factor: 3.869

Review 4.  Sex-specific lung diseases: effect of oestrogen on cultured cells and in animal models.

Authors:  Bosung Shim; Gustavo Pacheco-Rodriguez; Jiro Kato; Thomas N Darling; Martha Vaughan; Joel Moss
Journal:  Eur Respir Rev       Date:  2013-09-01

5.  Sex disparities in cancer mortality and survival.

Authors:  Michael B Cook; Katherine A McGlynn; Susan S Devesa; Neal D Freedman; William F Anderson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-07-12       Impact factor: 4.254

6.  Estrogen receptor beta (ERbeta) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells.

Authors:  Pamela A Hershberger; Laura P Stabile; Beatriz Kanterewicz; Mary E Rothstein; Chris T Gubish; Stephanie Land; Yongli Shuai; Jill M Siegfried; Mark Nichols
Journal:  J Steroid Biochem Mol Biol       Date:  2009-05-19       Impact factor: 4.292

7.  The role of estrogen, progesterone and aromatase in human non-small-cell lung cancer.

Authors:  Nadiyah Kazmi; Diana C Márquez-Garbán; Lilia Aivazyan; Nalo Hamilton; Edward B Garon; Lee Goodglick; Richard J Pietras
Journal:  Lung Cancer Manag       Date:  2012-12

8.  Tobacco and estrogen metabolic polymorphisms and risk of non-small cell lung cancer in women.

Authors:  Michele L Cote; Wonsuk Yoo; Angela S Wenzlaff; Geoffrey M Prysak; Susan K Santer; Gina B Claeys; Alison L Van Dyke; Susan J Land; Ann G Schwartz
Journal:  Carcinogenesis       Date:  2009-01-27       Impact factor: 4.944

Review 9.  Estrogen receptors as the novel therapeutic biomarker in non-small cell lung cancer.

Authors:  Hideki Kawai
Journal:  World J Clin Oncol       Date:  2014-12-10

10.  Genetic variation in ESR2 and estrogen receptor-beta expression in lung tumors.

Authors:  Ji Young Song; Jill M Siegfried; Brenda Diergaarde; Stephanie R Land; Robert Bowser; Laura P Stabile; Sanja Dacic; Rajiv Dhir; Tomoko Nukui; Marjorie Romkes; Joel L Weissfeld
Journal:  Cancer Epidemiol       Date:  2013-04-23       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.